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Summary ZD1694 (Tomudex, raltitrexed) is a specific quinazoline antifolate thymidylate synthase inhibitor that relies on polyglutamation for
high potency. Antibodies to ZD1694 have been used to establish a sensitive radioimmunoassay as an alternative to high-performance liquid
chromatography (HPLC). The radioimmunoassay is reproducible, accurate and provides a means of determining low levels of ZD1694 in
plasma (< 1 nM). By virtue of the high cross-reactivity of the antibodies with polyglutamated forms of ZD1694, it is also possible to measure
the total concentration of drug in tissues. Results obtained in L1210 mouse leukaemia cells and in mouse tissues were similar to those
previously determined using radiolabelled drug. Pharmacokinetic studies in mice have confirmed thatthe compound is rapidly eliminated from
the plasma and that there is a prolonged terminal elimination phase. ZD1694 was measured in plasma (0.56 ng ml-1; 1.2 pmol ml-') up to
7 days after a single i.p. dose of 100 mg kg-' ZD1694. Liver, kidney and gut epithelium had a substantially higher level of ZD1694
immunoreactivity than plasma. For example, 24 h after a single i.p. dose at 1, 10 and 100 mg kg-', total drug levels in the liver were 480, 325
and 152 times higherthan plasma levels respectively. In kidney and gut epithelium, total drug levels atthese doses were approximately 55 and
34 times those of plasma. The high tissue to plasma ratios were maintained for at least 7 days after administration. Similarly, high tissue to
plasma ratios (> 100) were found in dogs treated with a clinically relevant dose of ZD1694. These were maintained for 4 weeks in liver and
kidney tissue (> 100). Total gastrointestinal concentrations of ZD1694 were approximately 10 times higher than plasma 3 days after
administration, but levels were neartothe limit of detection at4 weeks. These results are consistent with extensive polyglutamation ofZD1694
within tissues in both mice and dog and provide further support for the infrequent schedule that has been used clinically. Although it has not
been possible to measure individual polyglutamated forms of ZD1694, the radioimmunoassay provides a convenient means of assessing total
drug levels in tissues and is currently the only method suitable for measuring the extent of drug retention in normal tissue and tumour biopsies
obtained from patients treated with ZD1694.
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Thymidylate synthase (TS; EC 2.1.1.45), which converts dUMP to
thymidylate, plays an essential role in the synthesis of DNA. In
recent years this enzyme has received much attention as a
chemotherapeutic target (Nord and Martin, 1993; Jackman and
Calvert, 1995), and several compounds are at various stages of
drug development. One ofthese, ZD1694 (Tomudex, raltitrexed), a
quinazoline antifolate (Jackman et al, 1991a, 1995a), has
progressed to broad phase II (Zalcberg et al, 1995; Smith et al,
1996) and phase III clinical studies in advanced colorectal cancer
(Cunningham et al, 1995). Tomudex is now available for the treat-
ment ofadvanced colorectal cancer in several countries.
ZD1694 inhibits TS with a Kj for the mouse enzyme of 60 nM
(Jackman et al, 1991a), is actively transported into cells through
the reduced folate carrier (RFC) and then rapidly metabolized by
the enzyme folylpolyglutamate synthetase (FPGS). The polygluta-
mated forms of ZD1694 are more effective inhibitors of TS
than the parent compound (e.g. the Kj for mouse enzyme of the
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tetraglutamate metabolite is 1 nM) and are also retained within cells
(Jackman et al, 1991a; Gibson et al, 1993). The prolonged inhibi-
tion of TS in intact cells (Jackman et al, 1995b; Aheme et al,
1996a), even after removal ofdrug from the medium, is consistent
with the formation and retention of active intracellular polygluta-
mated species. High circulating levels of thymidine in mouse
models compared with those in man complicate the anti-tumour
evaluation of TS inhibitors (Jackman et al, 1984, 1995a), but
ZD1694 was curative in DBA2 mice bearing the intramuscular
L5178Y TK-/- mouse lymphoma by a single i.p. injection (10 mg
kg-') (Jackman et al, 1991b). In thymidine salvage competent
models, repeated treatment over 5 days with ZD1694 led to anti-
tumour activity (Jackman et al, 1991a and b). Prolonged TS inhibi-
tion in the tissues and tumours of mice (presumably due to drug
retention) was thebasis forthe once every 3 weeks schedule used in
clinical studies (Jackman et al, 1995a; Clarke et al, 1996).
ZD1694 has previously been measured in plasma by reversed-
phase HPLC (Jodrell et al, 1991). The limit of detection of this
assay for plasma was 0.2 g1M when a solid-phase extraction was
used. In mice treated with 100 mg kg-', plasma levels could be
followed for up to 10 h. The analysis showed that the drug is elim-
inated rapidly from the plasma (with a half-life of - 30 min), and
there was also a furtherprolonged phase ofelimination (-6.5 h). A
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long terminal plasma elimination phase of ZD1694 has also been
measured in man using '4C-radiolabelled compound (Judson et al,
1996). Drug was measured in the plasma (1-10 ng ml-') forup to4
weeks after drug administration, giving a third phase half-life of
257 h. In a phase I trial ofthe drug (Clarke et al, 1996), no correla-
tions between plasma pharmacokinetic parameters (Cmax or AUC)
and clinical outcome (toxicity or response) were found.
Because ofthe highly polyglutamatable nature ofZD1694, total
concentration of drug (parent compound and polyglutamates) in
tissues and tumour is likely to be a more important determinant of
clinical outcome than plasmadrug levels. Polyglutamated forms of
the quinazoline antifolates have previously been measured in vitro
using radiolabelled drugs. Separation of polyglutamated metabo-
lites by HPLC was followed by quantitation in fractions using
radiochemical analysis (Jackman et al, 1991c; Gibson et al, 1993)
or by measuring inhibition of TS (Sikora et al, 1988). In prelimi-
nary experiments, direct evidence of polyglutamation in tissues
has been obtained by administration ofradiolabelled drug to mice
(Jackman et al, 1995a). Total drug concentrations in liver, kidney
and intestinal epithelium were 30- to 100-fold higher than in the
plasma 24 h after a single injection of tritiated ZD1694
(5 mg kg-'), and most of the radioactivity (-80%) in the tissues
was present as polyglutamates. No polyglutamates were found in
mouse plasma.
However, the use of radiolabelled ZD1694 is not suited to
extended pharmacokinetic studies or to any clinical studies on
tissue and tumour drug retention. As part of our efforts to provide
further evidence forthe importance ofpolyglutamation in the phar-
macology and activity ofTomudex, a sensitive radioimmunoassay
has been used to compare the total drug concentrations in mouse
and dog tissues with those in plasma. The dog was chosen as an
additional model, because, unlike mice, plasma levels ofthymidine
are low and this species is much more sensitive to the effects ofTS
inhibitors than rodents. Dog toxicity studies were found to predict
well for the maximum-tolerated dose of ZD1694 in clinical trials
(data on file, Zeneca Pharmaceuticals). Thus this animal model
would be expected to give a good indication ofZD1694 concentra-
tions in human tissues at a relevant therapeutic dose.
METHODS
Sheep antiserum to ZD1694 (S37B14) was provided by Zeneca
Pharmaceuticals and was stored at 4°C with the addition of 0.1%











The cross-reactants were incubated at various concentrations with the
ZD1694 antiserum and radiolabelled ZD1 694, as described in the methods.
Percentage cross-reactivity is the relative amount of ZD1694 and cross-
reactant required to inhibit antibody binding of radiolabel by 50%.
sodium azide. Tritiated ZD1694 (19.1 Ci mmol-1) was prepared
by Cambridge Research Biochemicals and supplied by Zeneca
Pharmaceuticals. Acetonitrile was from Fisons, Dextran T70 from
Pharmacia and all other chemicals from Sigma. Solutions were
prepared with deionized water. ZD1694 was supplied by Zeneca
Pharmaceuticals, and the synthesis ofthe polyglutamated forms of
ZD1694 and its analogues has been previously described (Hughes
et al, 1990; Bisset et al, 1992; Bavetsias et al, 1993).
Stock solutions (10 mM) were prepared in 0.15 M sodium bicar-
bonate and stored at -20°C. For the mouse studies, the drug was
formulated in 0.05 M sodium bicarbonate and the pH was adjusted
to 8.5-9.0.
Radioimmunoassay
The assay diluent was 0.05 M phosphate buffer pH 7.4, containing
1 g 1-' gelatin and 6 g 1-' sodium chloride (PBSG). Initially, all
dilutions and dispensing ofstandards and samples were made with
a Dilutrend diluter, but a Multiprobe (Canberra Packard) auto-
mated liquid-handling system was later programmed to perform
these steps in the assay. A working standard solution of ZD1694
(100 ig ml-') was stored in aliquots at-20°C and diluted in PBSG
for each assay to cover the range of the standard curve. Samples
were assayed at three appropriate dilutions to ensure that the
results ofat least two dilutions fell on the linearportionofthe stan-
dard curve, and samples were reassayed at different dilutions if
necessary. The antiserum was diluted in PBSG so that approxi-
mately 40% oftotal radioactivity was bound (Bo) to antibody. This
dilution was previously determined from an antiserum dilution
curve and was 1:300 to 1:500 depending on the batch ofradiolabel
used. [3H]ZD1694 was also diluted (from a sub-stock stored at
-20°C) in PBSG so that approximately 3 pmol (in 100gl) was
added to each assay tube.
Diluted standards and samples (0.1 ml) were added in duplicate
to numbered LP3 tubes (Luckham) or to deep-well blocks
(Beckman) with 0.3 ml of assay diluent, 0.1 ml of diluted anti-
serum and 0.1 ml of diluted label, mixed and left to stand in iced
water for 1 h. Each assay included total counts and non-specific-
binding tubes, containing only the radiolabel and buffer, and zero-
standard-binding tubes (Bo), which contained only radiolabel and
antiserum. The antibody-bound radiolabel was separated from
unbound radiolabel by the addition of ice-cold dextran-coated
charcoal [2.5% (w/v) activated charcoal (Sigma) coated with
0.25% (w/v) Dextran T-70 (Pharmacia)] to all but the total-counts
tubes for 10 min. After centrifugation at 1000g for 10 min at 4°C,
0.5 ml aliquots of supematant were taken from each assay tube
for scintillation counting in 4.0 ml of Ultima gold scintillant
(Canberra-Packard). The ZD1694 concentrations in the samples
were calculated from the standard curve with a data reduction
programme that used a four-parameter logistic plot (RiaSmart,
Canberra-Packard). The radioimmunoassays were carried out at
the Institute ofCancer Research.
Intracellular drug levels
L1210 mouse leukaemia cells (2-3 x 106) and an acquired resis-
tant variant of the cell line (LI21OR:D1694; 6-8x106 cells), which
has an impaired ability to polyglutamate ZD1694 (Jackman et al,
1995c), were exposed to ZD1694 (0.1 gM and 1 gM) for 4 or 24 h
and, afterharvesting and washing as described previously (Gibson
et al, 1993; Jackman et al, 1995c), were resuspended in 0.5 ml of
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Table 2 Intracellular concentrations of ZD1694 in Li210 mouse leukaemia
cells and an acquired resistant variant with impaired ability to polyglutamate
antifolates
Cell line ZD1694 exposure Intrace
L1210 0.1 gM,4h 1.0
0.1 gmM,24h 4.6
L1210:RD1694 0.1 gM, 24 h ND
L1210 1 gM, 4 h 5.9
lgM,24h 17.2
L1210:RD1694 1 mM, 24 h 0.1
Each extract was assayed in duplicate at three dilutions.
concentrations were based on a L1210 cell volume of 0.6
none detected. The limit of detection for 6-8 x 106 cells is
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Figure 1 The disappearance of ZD 1694 (5 mg kg-' i.p.)
female DBA2 mice (n = 3). Error bars are ± s.d. and are v
the 1-h time point. The 2- and 24-h time points are the m(
Predicted concentrations (*) were obtained using a non-cl
model (PCNonlin)
PBSG and frozen. After thawing, the cells were sonicated for 3 x
30 s, the supernatant clarified by centrifugation (1000 g for 10
min) and then assayed at three dilutions.
Mouse pharmacokinetic studies
'~t ' 9Female DBA2 mice aged between 7 and 9 weeks were treated in
groups of three with a single i.p. injection (0.1 ml per 10 g) of
8 ± 0.56 (n = 4) ZD1694 (5 mg kg-'). Blood was obtained by cardiac puncture
(19.7/14.7) under anaesthetic after 0.5, 1, 2, 4, 9 and 24 h. Mice were also
2 (0.14/0.10) treated i.p. at 1, 10 and 100 mg kg-' ZD1694; blood, liver and
kidney were obtained 24 h later and, additionally, for animals
Intracellular treated with 100 mg kg-', 2, 4 and 7 days later to assess tissue
i3 x 10-12 I. ND, retention of ZD1694. Plasma was immediately separated from the
; approximately blood by microcentrifugation and stored at -20°C until assayed.
Liver and kidney samples were immediately frozen on solid
carbon dioxide. Gut epithelium samples were obtained 1 day after
drug treatment. A section (5-15 cm below the stomach) of upper
small intestine was flushed through with cold 0.1 M Tris-acetate
buffer pH 10 and slit open; the epithelium was scraped into a
weighed glass pot containing 0.5 ml of Tris buffer and stored
frozen.
Plasma samples were assayed directly in the radioimmunoassay
at three dilutions depending on the dose and time since administra-
tion. Liver and kidney tissues were thawed, weighed and homoge-
nized with two volumes 0.1 M Tris-acetate buffer pH 10 and
aliquots of homogenates (0.5 ml) were treated with an equal
volume ofacetonitrile. The weighed gut-scrape samples were soni-
cated for 30 s and also extracted with an equal volume of acetoni-
trile. After centrifugation to remove particulate matter (8000 g for
20 25 10 min), the tissue extracts were aspirated and diluted with PBSG
before radioimmunoassay. Again, three dilutions in duplicate were
assayed.
Pharmacokinetic studies in dogs
)from the plasma of
vithin the symbol for ZD1694 (0.2 mg kg-') was administered by single intravenous
ompartmental bolus injection to pairs of Alderley Park Beagle dogs (one female
and one male dog). Blood was obtained from one pair 4 h, 24 h, 3,
Table 3 Plasma ZD1694 concentrations and total ZD1694 immunoreactivity in tissues 1-7 days after a single i.p.
administration of ZD1694 in female DBA2 mice
Dose Day Plasma (ng ml)-' Tissue (nmol g-1) ZD1694 equivalents
(mg kg)-1 (tissue-plasma ratio)
Liver Kidney Gut epithelium
1 1 2.26 1.1 2.28±0.8 0.32±0.1 0.17±0.05
(4.75 2.3)a (480) (67) (36)
10 1 3.42 1.0 2.33 ± 0.6 0.38 ± 0.08 0.36 (0.38: 0.33)
(7.18 2.1)a (325) (53) (50)
100 1 14.6±7.3b 4.65±2.8b 1.40±0.2b 0.53±0.09
(30.67 15.3)a (152) (46) (17)
2 4.0±0.6 0.86±0.3 0.46±0.1 ND
(8.40 ± 1.3)a (102) (55)
4 1.14±0.4 0.41 ±0.12 0.22±0.06 ND
(2.39 +0.8)a (172) (92)
7 0.56±0.1 0.15±0.07 0.10±0.02 ND
(1.18 0.2)a (127) (85)
aValues as pmol ml-1. bResults from two experiments. Values are the mean s.d. of three animals per group.
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7, 14, 21 and 28 days after dosing. On day 28, the animals were
sacrificed and liver, kidney and gastrointestinal tissues (8-inch
sections of duodenum, jejunum, ileum and colon) were obtained.
The dogs from the other two pairs were bled, and tissues were
harvested 24 h and 72 h after dosing. One dog was treated with
saline and used to provide control samples. Plasma, liver (2-g
samples) and kidney (2-g slices from a kidney cut tangentially to
include cortex and medulla) were immediately frozen on Cardice
and stored at -70°C until processed, as described for mouse
tissues. The gastrointestinal samples were placed on ice and cut
longitudinally and then washed with ice-cold saline to remove the
contents; the epithelium was scraped with a spatula and placed in




The ZD1694 standard curve ranged from 0.1 to 10 ng ml-1
(0.21-21 nM) and the mean dose at 50% inhibition ofbinding was
0.7 ± 0.05 ng ml-1 (1.47 nM). The sensitivity of the curve as
determined by a 3-s.d. fall in binding from the Bo value was
0.1 ng ml-'. To eliminate minor matrix effects, plasma
samples were diluted at least 1:2, giving a limit of detection of
0.2 ng ml-1 (0.42 pmol ml-1). The recovery of ZD1694 added to
drug-free plasma was complete over a concentration range of
1-500 ng ml-1 (96.4 ± 8.7%). Within and between assay variation
was 14.0 ± 1.5 ng ml-1, CV 10.7%, and 14.7 ± 1.9 ng ml-1, CV
12.9%, respectively.
The cross-reaction ofthe antiserum with reduced folates and the
polyglutamated forms ofthe drug is shown in Table 1. As expected
the polyglutamated metabolites are recognized to essentially the
same extent as the parent compound. This cross-reaction has been
exploited to measure total ZD1694 immunoreactivity in tissues. To
minimize effects of acetonitrile extracts on antibody binding, it
was necessary to dilute extracts at least 10-40 times before assay,
depending on the tissue assayed. Thus, taking into account all the
dilutions involved in the procedure, the limit of detection for
liver, kidney and gut epithelium extracts were 0.06, 0.03 and
0.015 nmol g-', respectively, although, in practice, extracts were
normally diluted at least 50 times before assay so that antibody
binding fell on the linear portion ofthe standard curve. Even with
these high-extract dilutions, it was possible to measure ZD1694
for prolonged periods after drug administration (see later). The
recovery of ZD1694 (105-1050 nM) added to tissue homogenates
was 113.3 ± 18.6%, and mean interassay variation for tissue
measurement was 11.9%. Results obtained between experiments
were similar. For example, mice were treated on three occasions
with 100 mg kg-' ZD1694, and results for liver extracts obtained 6
days later were not significantly different (0.73 ± 0.18, 0.67 ± 0.42
and 0.58 ± 0.18 nmol g-1). The tissue levels of ZD1694 obtained
by radioimmunoassay were similar to those measured previously
using radioactive drug. At 24 h after a single 5 mg kg-1 i.p. injec-
tion of ZD1694, total drug liver levels measured by radio-
immunoassay were not significantly different (1.29 ± 0.27 nmol g-'
(n = 4) (P > 0.25) from those measured in radioactive experiments
(0.93 ± 0.5 nmol g-' (n = 3) (Jackman et al, 1995a).
Intracellular ZD1694
As part ofthe validation ofthe radioimmunoassay for the measure-
ment of total concentrations of ZD1694 (i.e. drug plus polygluta-
mated forms), results obtained on extracts of cells grown in the
presence ofdrug were compared with those previously obtained by
radioassay after exposure to radioactive drug. The intracellular
concentration of ZD1694 in L1210 cells exposed to the drug
(0.1 JIM) for 4 h was 1.04 ± 0.25 gM compared with 2.9 ± 1.2gM
determined by radioassay. At 24 h the intracellular concentration
was 4.65 gM compared with 3.8gM by radioassay (Jackman et al,
1995c). No immunoreactivity was measurable in the L1210:RD1694
cells after a 24-h exposure to 0.1FIM. At 1 gM drug exposure,
immunoreactivity was just measurable (0.12gM) in the resistant
cells, the parent line accumulating approximately 150 times more
drug atthis dose (Table 2). Fortheresistantline, theradioassay esti-
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Figure 2 Total ZD1694 concentrations in the plasma (x), liver (*), kidney
(A), duodenum (X), ileum (V), jejunum (*) and colon (-) of dogs treated
with 0.2 mg kg-' ZD1694 (single i.v. bolus). Results are the means of two
dogs, *except at 24 and 72 h at which n = 4 (mean ± s.d.). In gastrointestinal
epithelium, concentrations were at the limit of detection (0.015 nmol g-1) by
day 28
ZD1694 plasma and tissue concentrations in DBA2
mice
The disappearance of ZD1694 from the plasma of DBA2 mice
given 5 mg kg-1 i.p. is shown in Figure 1. ZD1694 rapidly disap-
pearedfromtheplasmawith an elimination phase ofapproximately
2.7 h (Non-compartmental model; PCnonlin) and drug was still
measurable at 24 h. Plasma and tissue levels ofZD1694 24 h after
1, 10 and 100 mg kg-1 i.p. doses are shown in Table 3. Plasma drug
concentrations increased with dose and there was evidence of a
prolonged terminal elimination phase in mice treated with
100 mgkg-1 ZD1694. By 7 days, plasmaconcentrations ofZD1694
were 0.56±0.1 ngml-1 (1.18±0.2pmolml-1). Total ZD1694
immunoreactivity in tissues also declined with time but, at all doses
and times studied, exceededthose ofplasma(liverat least 100-fold,
25 30 kidney at least 46-fold and gut epithelium at least 17-fold).
ZD1694 plasma and tissue concentrations in dogs
The total drug concentrations in the plasma and tissues from dogs
treated with ZD1694 are shown in Figure 2. As plasma samples
were obtained at only two time points during the first day, the early
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plasma distribution and elimination drug kinetics have not been
defined. However, it is apparent that drug elimination within the
first 24 h is rapid and that a long terminal elimination phase is
present, plasma concentrations declining to approximately
0.4 ng ml-'; 0.85 pmol ml-' 28 days after drug administration.
Total ZD1694 immunoreactivity in liver and kidney was at least
100 times that in plasma throughout the 28 days ofthe study. In the
gastrointestinal tissues (duodenum, jejunum, ileum, colon), total
immunoreactivity was approximately 10 times that of plasma 24
and 72 h after administration but had declined so that at 28 days
drug concentrations were at or near the limit of detection of the
assay (0.015 nmol ml-'). There were no consistent differences
between female and male dogs.
DISCUSSION
Because of the high potency of ZD1694 and its rapid elimination
from plasma (Jackman et al, 1991a; Jodrell et al, 1991), a highly
sensitive assay is required for extended pharmacokinetic studies;
radioimmunoassay offers an attractive altemative to HPLC. A
sheep antiserum to ZD1694 has been used for the radioim-
munoassay of plasma samples and it is specific and sensitive with
consistent day-to-day performance. As there is as yet no evidence
of plasma and urinary metabolites of ZD1694 (Jodrell et al, 1991;
Judson et al, 1996), plasma drug measurements made with the
antiserum can be considered to be specific for ZD1694. The
remarkable ability of antisera to distinguish between antifolates
and natural folates has been shown before (Levine and Powers,
1974; Aheme et al, 1977) and the low cross-reaction of the
ZD1694 antiserum with reduced folates was therefore not
surprising. From previous work, it is also to be expected (Anzai et
al, 1987) that polyglutamated forms of antifolates will be recog-
nized to a similar extent as the monoglutamate.
The plasma pharmacokinetics of ZD1694 (5 mg kg-' i.p.) in
mice have been measured using the radioimmunoassay. The calcu-
lated half-life is similar to previous estimates determined by HPLC
but after a much higher dose (100 mg kg-' i.p.) (Jodrell et al,
1991). Further, evidence of a slower phase ofelimination has been
obtained in this study and, after 100 mg kg-', plasma concentra-
tions of ZD1694 were still measurable at least 7 days after drug
administration. Additionally, in dogs, ZD1694 was still present in
plasma 28 days after administration, which is consistent with the
long terminal half-life reported in patients (Judson et al, 1996).
The importance of this prolonged period of plasma ZD1694 expo-
sure remains to be established.
At the three doses used in this study, total ZD1694 immuno-
reactivity in mouse liver and kidney were> 100-fold and -55-fold
higher, respectively, at 24 h than plasma concentrations ofZD1694
(Table 3). At 100 mg kg-', this ratio remained high, at least until
7 days after drug administration. High tissue to plasma ratios
(-34-fold) were also observed in gut epithelium at 24 h. Similarly,
in the dog, there was considerable accumulation of immuno-
reactive ZD1694 in liver and kidney (100-150 times) compared
with plasma, although in the gastrointestinal epithelium the
tissue to plasma ratio was lower (approximately 10). The loss of
drug in these tissues by day 28 could be due to cell death,
hydrolysis and subsequent efflux of ZD1694 monoglutamate or to
dilution of ZD1694 drug species by cell division. These
observations are consistent with (but do not prove) the efficient
uptake and retention of ZD1694 as polyglutamated species within
the tissues.
Polyglutamation plays an important role in the activity of
several antifolates. Their measurement in tissue culture cells has
been achieved previously after incubation with radiolabelled
compounds followed by extraction and HPLC separation (Jolivet
et al, 1982; Sikora et al, 1988; Pizzomo et al, 1989; Jackman et al,
1991c; Gibson et al, 1993). Similar methodology has been used to
measure the polyglutamated forms of methotrexate in isolated
human leukaemic blast cells (Goker et al, 1993). Methotrexate
polyglutamates have been determined in human tissue samples
after high-dose therapy by using HPLC with subsequent detection
in fractions using radioimmunoassay (Anzai et al, 1987) or by
using the radioligand binding assay (Samuels et al, 1984). Total
methotrexate has also been measured by radioimmunoassay as a
measure of polyglutamation in erythrocytes from patient treated
with high-dose therapy (Schalhom et al, 1982).
A similar approach has been used in the present study. Our
initial experiments showed that the radioimmunoassay was not
sufficiently sensitive to determine the amounts ofindividual polyg-
lutamates in fractions obtained from HPLC. As the polyglutamates
of ZD1694 cross-react (on a molar basis) to essentially the same
extent as the parent drug, experiments were carried out to deter-
mine if this cross-reactivity could be used to measure total drug
levels (presumed to be ZD1694 parent drug and polyglutamates).
Firstly, total immunoreactivity measured in vitro and in vivo
compared well with measurements of total drug determined using
radiolabelled ZD1694. Secondly, it has previously been shown that
at 24 h the majority (80%) of radiolabelled ZD1694 in tissues was
present in the polyglutamated forms (Jackman et al, 1995b), and
the high tissue to plasma ratios described here are also presumed to
represent polyglutamated forms of this antifolate. Thirdly, the high
tissue to plasma ratios observed for ZD1694 in both mouse and
dog tissues are in contrast to those observed with non-polygluta-
mated quinazoline antifolates. For example, liver levels of
CB30900 were only sixfold higher than plasma levels, which were
similar to kidney concentrations (Walton et al, 1996). Similarly,
low tissue to plasma ratios were also observed for ZD933 1, a non-
polyglutamated TS inhibitor in clinical study (Aherme et al,
1996b). While this assay gives no indication of which polygluta-
mates are present, the duration and extent of drug retention in
tissues, thought to be primarily due to polyglutamation, can be
obtained. The concentration and retention of ZD1694 in tissues
provides further justification for the infrequent bolus administra-
tion being used clinically.
In summary, we have described a convenient and sensitive
radioimmunoassay for determining the concentration ofZD1694 in
biological samples. As the antiserum used cross-reacts with the
polyglutamated forms of ZD1694, total ZD1694 immunoreactivity
in tissues is thought to represent parent monoglutamate and poly-
glutamates. The initial rapid elimination ofZD1694 from plasma in
mice has been confirmed as well as the persistence of low plasma
drug levels described in mice and dogs. Total ZD1694 in normal
tissues (liver, kidney and gut epithelium) exceeded those ofplasma,
the high ratio being maintained in liver and kidney for at least 7
days in mice and 28 days in dogs afterthe administration ofa single
dose. The availability of this radioimmunoassay presently repre-
sents the most convenient means by which total drug levels
in tissues and tumours can be obtained preclinically, and it is
presently being used to provide information on the pharmaco-
kinetic/pharmacodynamic relationships ofZD1694 C Hardcastle et
al, 1997) in addition to the effects of potential rescue agents, such
as leucovorin (Jackman et al, 1995d). For clinical biopsy material
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(in which the amount of tissue available for assay is small), the
radioimmunoassay represents the only method that is currently
available for determining drug levels (Farrugia et al, 1997).
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